Cited by 371Blood Coagulation and Thrombosis MechanismsAdipokines, Inflammation, and Metabolic DiseasesProtease and Inhibitor Mechanisms

The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk

Open access

Juhan-Vague, I., Alessi, M-C., Mavri, A., Morange, P.E.·2003·Journal of Thrombosis and Haemostasis

DOI 10.1046/j.1538-7836.2003.00279.x

Open this paper in CoChat — free account

Abstract

Elevated plasma plasminogen activator inhibitor-1 (PAI-1) level is a core feature of insulin-resistance syndrome (IRS). Atherothrombotic complications in IRS are partly attributed to impaired fibrinolysis caused by increased plasma PAI-1 levels. Although the etiology of IRS is far from being explained, the clustering of inflammation, adipose tissue accumulation and insulin resistance suggests an etiopathological link. Proinflammatory cytokines might regulate PAI-1 expression in IRS; however, more studies are needed to confirm this complex mechanism in humans. Furthermore, modifying PAI-1 expression by PAI-1 inhibitors provides a new challenge and may reveal the true role of PAI-1 in atherosclerotic and insulin resistance processes.

Integrity signals

Registry

Crossref · 10.1046/j.1538-7836.2003.00279.x

Cites

95 of 95 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Prevalence of the Metabolic Syndrome Among US Adults: Findings From the Third National Health and Nutrition Examination Survey
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
Pradhan, A. D. (2001) · JAMA · doi:10.1001/jama.286.3.327 · Cited by 4,433
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
IRS-1-Mediated Inhibition of Insulin Receptor Tyrosine Kinase Activity in TNF-α- and Obesity-Induced Insulin Resistance
Hotamisligil, G. S., Peraldi, P., Budavari, A., Ellis, R., White, M. F., & Spiegelman, B. M. (1996) · Science · doi:10.1126/science.271.5249.665 · Cited by 2,630
C-Reactive Protein in Healthy Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction: A Potential Role for Cytokines Originating From Adipose Tissue?
Yudkin, J. S., Stehouwer, C. D. A., Emeis, J. J., & Coppack, S. W. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.4.972 · Cited by 2,465
Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome
Festa, A., D’Agostino, R., Howard, G., Mykkänen, L., Tracy, R. P., & Haffner, S. M. (2000) · Circulation · doi:10.1161/01.cir.102.1.42 · Cited by 2,366

Show all 95 references

Research works printed but not linked: 1

Mohamed-Ali, 1997, Human subcutaneous adipose tissue secretes interleukin-6 but not tumour necrosis factor-αin vivo, J Clin Endocrinol Metab, 82, 4196

Sorted by citations

Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Adipose Tissue as an Endocrine Organ
Kershaw, E. E., & Flier, J. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0395 · Cited by 5,522
Inflammation: the link between insulin resistance, obesity and diabetes
Dandona, P. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.10.013 · Cited by 2,170
Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease
Jung, U. J., & Choi, M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046184 · Cited by 1,971
“vascular cells, such as preadipocytes, fibroblasts, vascular endothelial cells, and a variety of immune cells, in adipose tissue, and its levels in plasma are increased in obesity and insulin resistance [128,129].”
Background
Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
Fahed, G., Aoun, L., Bou Zerdan, M., Allam, S., Bou Zerdan, M., Bouferraa, Y., & Assi, H. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020786 · Cited by 1,441
“Together, RAS, LOX-1, and ROS form a positive feedback loop and induce a vicious cycle of endothelial dysfunction, inflammation, and fibroblast proliferation, leading to the progression of dyslipidemia, T2DM, hypertension, vasculopathies, and CVDs [63–65].”
BackgroundInfluential
The Metabolic Syndrome
Grundy, S. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,227
Metabolic syndrome: pathophysiology, management, and modulation by natural compounds
Rochlani, Y. M., Pothineni, N. V. K., Kovelamudi, S., & Mehta, J. L. (2017) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944717711379 · Cited by 1,228
Dietary factors and low-grade inflammation in relation to overweight and obesity
Calder, P. C., Ahluwalia, N., Brouns, F., Buetler, T., Clement, K., Cunningham, K., Esposito, K., Jönsson, L. S., Kolb, H., Lansink, M., et al. (2011) · British Journal of Nutrition · doi:10.1017/s0007114511005460 · Cited by 1,098
“C motif) ligand; CCR, CC chemokine receptor; CFU, colony forming units; CLA, conjugated linoleic acids; CRP, C-reactive protein; DQI, Diet Quality Index; DQI-R, revised Diet Quality Index; GI, glycaemic index; GL, glycaemic load; HEI, healthy eating index; IFN, interferon; IL-1ra, IL-1 receptor antagonist; IRS, insuli…”
Influential
Mechanisms of obesity-associated insulin resistance: many choices on the menuPreprint
Qatanani, M., & Lazar, M. A. (2007) · Genes & Development · doi:10.1101/gad.1550907 · Cited by 797
“Plasma PAI-1 levels are elevated in obesity and insulin resistance and predict future risk for T2DM (Mertens and Van Gaal 2002; Juhan-Vague et al. 2003).”
Background
Cross Talk Pathways Between Coagulation and Inflammation
Foley, J. H., & Conway, E. M. (2016) · Circulation Research · doi:10.1161/circresaha.116.306853 · Cited by 595
Obesity as a risk factor in venous thromboembolism
Stein, P. D., Beemath, A., & Olson, R. E. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.03.012 · Cited by 588
Biology of Stem Cells in Human Umbilical Cord Stroma: In Situ and In Vitro Surveys
Karahüseyinoğlu, S., Çınar, Ö., Kılıç, E., Kara, F., Akay, G. G., Demiralp, D. Ö., Tükün, A., Uçkan, D., & Can, A. (2006) · Stem Cells · doi:10.1634/stemcells.2006-0286 · Cited by 527
REVIEW: Plasminogen Activator Inhibitor‐1 (PAI‐1): A Key Factor Linking Fibrinolysis and Age‐Related Subclinical and Clinical Conditions
Cesari, M., Pahor, M., & Incalzi, R. A. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00171.x · Cited by 470
Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population
Srikanthan, K., Feyh, A., Visweshwar, H., Shapiro, J. I., & Sodhi, K. (2015) · International Journal of Medical Sciences · doi:10.7150/ijms.13800 · Cited by 458
“The link between PAI-1 and metabolic syndrome has been long established with elevated levels being strongly correlated such that the more severe the metabolic syndrome, the higher the PAI-1 [51-53].”
BackgroundInfluential
Diagnosis and management of the metabolic syndrome
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Current Opinion in Cardiology · doi:10.1097/01.hco.0000200416.65370.a0 · Cited by 437
Sarcopenia, obesity, and inflammation—results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors study
Cesari, M., Kritchevsky, S. B., Baumgartner, R., Atkinson, H. H., Penninx, B. W. J. H., Lenchik, L., Palla, S. L., Ambrosius, W. T., Tracy, R. P., & Pahor, M. (2005) · American Journal of Clinical Nutrition · doi:10.1093/ajcn.82.2.428 · Cited by 432
“Our results also confirm evidence from previous studies that showed a relation between BMI and total fat mass and markers of inflammation and fibrinolysis (14, 18, 24, 35).”
BackgroundResult
PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences
Alessi, M.-C., & Juhan-Vague, I. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000242905.41404.68 · Cited by 390
Self-citation
Insulin resistance and cardiovascular disease
Kosmas, C. E., Bousvarou, M. D., Kostara, C. E., Papakonstantinou, E. J., Salamou, E., & Guzman, E. (2023) · Journal of International Medical Research · doi:10.1177/03000605231164548 · Cited by 434
“VAT secretes PAI-1, thus explaining its connection with obesity-related insulin resistance.(64,65) The PAI-1 genotype seems to affect the vascular risk linked to hyperinsulinemia.”
Background
Blood Coagulation: Hemostasis and Thrombin Regulation
Tanaka, K. A., Key, N. S., & Levy, J. H. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31819bcc9c · Cited by 357
“PAI-1 is a serine protease inhibitor synthesized in the liver and endothelium, and its expression is increased in inflammatory states.(139)”
Background
The Prebiotic Potential of Inulin-Type Fructans: A Systematic Review
Hughes, R., Alvarado, D. A., Swanson, K. S., & Holscher, H. D. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab119 · Cited by 335
“PAI-1 is positively associated with inflammation and insulin resistance and may be regulated by proinflammatory cytokines (116).”
Background
Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome
Yang, G., Badeanlou, L., Bielawski, J., Roberts, A. J., Hannun, Y. A., & Samad, F. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.91014.2008 · Cited by 295
“1), as well as plasminogen activator inhibitor-1 (PAI-1) (19, 29).”
BackgroundInfluential
Cyanidin 3-glucoside ameliorates hyperglycemia and insulin sensitivity due to downregulation of retinol binding protein 4 expression in diabetic mice
Sasaki, R., Nishimura, N., Hoshino, H., Isa, Y., Kadowaki, M., Ichi, T., Tanaka, A., Nishiumi, S., Fukuda, I., Ashida, H., et al. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.08.008 · Cited by 307
The Placenta Cytokine Network and Inflammatory Signals
Mouzon, S. H., & Guerre-Millo, M. (2005) · Placenta · doi:10.1016/j.placenta.2005.08.009 · Cited by 295
Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease
Dellas, C., & Loskutoff, D. J. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-01-0033 · Cited by 285
“significantly reduces plasma PAI-1 levels in obese individuals (113).”
BackgroundInfluential
Altered Adipose and Plasma Sphingolipid Metabolism in Obesity
Samad, F., Hester, K. D., Yang, G., Hannun, Y. A., & Bielawski, J. (2006) · Diabetes · doi:10.2337/db06-0330 · Cited by 285
“For example, plasminogen activator inhibitor-1 (PAI-1), the primary inhibitor of plasminogen activation in vivo and an established risk factor for cardiovascular disease is dramatically elevated in adipose tissues of obese mice and humans (3,5).”
Background
Adipokines: New potential therapeutic target for obesity and metabolic, rheumatic, and cardiovascular diseases
Recinella, L., Orlando, G., Ferrante, C., Chiavaroli, A., Brunetti, L., & Leone, S. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.578966 · Cited by 261
Role of macrophage tissue infiltration in metabolic diseases
Bouloumié, A., Curat, C. A., Sengenès, C., Lolmède, K., Miranville, A., & Busse, R. (2005) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000172571.41149.52 · Cited by 268
Plasma leptin: Associations with metabolic, inflammatory and haemostatic risk factors for cardiovascular disease
Wannamethee, S. G., Tchernova, J., Whincup, P. H., Lowe, G. D. O., Kelly, A., Rumley, A., Wallace, A. M., & Sattar, N. A. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.04.012 · Cited by 210
Circulating inflammatory markers and risks of cardiovascular and non‐cardiovascular disease
Lowe, G. D. O. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01416.x · Cited by 211
Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review)
Varra, F., Varras, M. N., Varra, V., & Theodosis‐Nobelos, P. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13219 · Cited by 232
“Finally, the contribution of IR, to the promotion of atherogenic processes and the increase of CVD risk, is the development of a higher serum viscosity and a pro‑thrombotic state, caused by the increased levels of fibrinogen and PAI‑1 (34,165,169,248‑253).”
Background
Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes
Kahn, S. E., Zinman, B., Haffner, S. M., O’Neill, M., Kravitz, B. G., Yu, D., Freed, M. I., Herman, W. H., Holman, R. R., Jones, N. P., et al. (2006) · Diabetes · doi:10.2337/db06-0116 · Cited by 188
Metabolic syndrome and cardiovascular risk
Alshehri, A. (2010) · Journal of Family and Community Medicine · doi:10.4103/1319-1683.71987 · Cited by 184
“[16] These include increased production of in ﬂ ammatory cytokines [17] plasminogen activator inhibitor [18] and other bioactive products.”
Background
Microarray profiling of gene expression in human adipocytes in response to anthocyanins
Tsuda, T., Ueno, Y., Yoshikawa, T., Kojo, H., & Osawa, T. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.12.042 · Cited by 165
The clinical biochemistry of obesity.
Sikaris, K. A. (2004) · PubMed Central · Cited by 158
Fat poetry: a kingdom for PPARγ
Anghel, S. I., & Wahli, W. (2007) · Cell Research · doi:10.1038/cr.2007.48 · Cited by 160
Protection from High Fat Diet-induced Increase in Ceramide in Mice Lacking Plasminogen Activator Inhibitor 1
Shah, C., Yang, G., Lee, I., Bielawski, J., Hannun, Y. A., & Samad, F. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709950200 · Cited by 160
Progression of Plasminogen Activator Inhibitor-1 and Fibrinogen Levels in Relation to Incident Type 2 Diabetes
Festa, A., Williams, K., Tracy, R. P., Wagenknecht, L. E., & Haffner, S. M. (2006) · Circulation · doi:10.1161/circulationaha.106.616177 · Cited by 147
Hemostasis and aging
Franchini, M. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.06.004 · Cited by 145
“[102] Juhan-Vague I, Alessi MC, Mavri A, Morange PE.”
Background
Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis
Aso, Y. (2007) · Frontiers in bioscience · doi:10.2741/2285 · Cited by 147
“Plasma PAI-1 also is strongly correlated in subjects with metabolic syndrome and type 2 diabetes with metabolic syndrome components such as BMI, visceral fat, blood pressure, plasma insulin, triglyceride, free fatty acids, and HDL cholesterol (54-56).”
Background
Obesity, hypertension and insulin resistance
Sharma, A. M., & Chetty, V. T. (2005) · Acta Diabetologica · doi:10.1007/s00592-005-0175-1 · Cited by 152
“Inflammatory responses are stimulated [16], and prothrombotic effects can arise due to increases in fibrinogen and plasminogen activator inhibitor [17].”
Background
Metabolic Actions of Adipocyte Hormones: Focus on Adiponectin
Ahima, R. S. (2006) · Obesity · doi:10.1038/oby.2006.276 · Cited by 147
“Plasminogen activator inhibitor-1 is increased with visceral adiposity and associated with greater risk for thrombosis and cardiovascular complications (11).”
Background
Regulation of plasminogen activation on cell surfaces and fibrin
Urano, T., Castellino, F., & Suzuki, Y. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14157 · Cited by 140
Regulation and interactions in the activation of cell-associated plasminogen
My�h�nen, H., & Vaheri, A. I. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-4230-9 · Cited by 143
The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men
Wannamethee, S. G., Lowe, G. D. O., Shaper, A. G., Rumley, A., LENNON, L. T., & Whincup, P. H. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.12.031 · Cited by 135
Nanoformulations of natural products for management of metabolic syndrome
Taghipour, Y. D., Hajialyani, M., Naseri, R., Hesari, M., Mohammadi, P., Stefanucci, A., Mollica, A., Farzaei, M. H., & Abdollahi, M. R. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s213831 · Cited by 134
“Hyperinsulinemia also increases re-absorption of sodium in the kidneys through activation of sympathetic nervous system, improving the cardiac output and vasoconstriction of arteries, which will all lead to hypertension.(20,29)”
Background
Adipose Tissue and Adipokines: The Association with and Application of Adipokines in Obesity
Khan, M. A., & Joseph, F. (2014) · Scientifica · doi:10.1155/2014/328592 · Cited by 115
Blood coagulation and the risk of atherothrombosis: a complex relationship.
Spronk, H. M. H., van der Voort, D., & Cate, H. T. (2004) · Thrombosis Journal · doi:10.1186/1477-9560-2-12 · Cited by 116
“However, it is questionable to what extend endothelial cells contribute to PAI-1 production in patients with atherosclerosis, since at least in patients with the metabolic syndrome, adipocytes and hepatocytes are more prominent sites of PAI-1 synthesis in relation to plasma PAI-1 [45].”
BackgroundInfluential
A Diet Rich in High-Oleic-Acid Sunflower Oil Favorably Alters Low-Density Lipoprotein Cholesterol, Triglycerides, and Factor VII Coagulant Activity
Allman-Farinelli, M. A., Gomes, K. E. P., Favaloro, E. J., & Petocz, P. (2005) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2005.04.008 · Cited by 115
Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study
Canonico, M., Oger, E., Conard, J., Meyer, G., Levesque, H., Trillot, N., Barrellier, M. ‐., Wahl, D. G., Emmerich, J., & Scarabin, P. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01933.x · Cited by 113
Assessment of Hemostatic Risk Factors in Predicting Arterial Thrombotic Events
Feinbloom, D. B., & Bauer, K. A. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000181762.31694.da · Cited by 112
Association between the A?2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus
Simeoni, E., Hoffmann, M. M., Winkelmann, B. R., Ruiz, J., Fleury, S., Boehm, B. O., M�rz, W., & Vassalli, G. (2004) · Diabetologia · doi:10.1007/s00125-004-1494-4 · Cited by 109
“Obesity, insulin resistance and diabetes mellitus share a Abbreviations: CAD, coronary artery disease · HOMAIR, homeostasis model assessment of insulin resistance · MCP-1, monocyte chemoattractant protein-1 · MIP-1α, macrophage inflammatory protein-1α · NF-κB, nuclear factor-κB · PAI-1, plasminogen-activator inhibitor…”
Background
Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel
Shepherd, J., Betteridge, J. D., Gaal, L. V., & Panel, O. B. O. A. E. C. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x43677 · Cited by 100
Circulating procoagulant microparticles in obesity
Goichot, B., Grunebaum, L., Desprez, D., Vinzio, S., Meyer, L., Schlienger, J.-L., Lessard, M., & Simon, C. (2006) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70251-3 · Cited by 99
“Various hemostasis abnormalities have been described in obesity, mainly concerning fibrinolysis and in particular increased PAI-1 [2], but other anomalies of coagulation factors and platelets have been reported [3].”
Background
Type 2 diabetes – An autoinflammatory disease driven by metabolic stress
Gonzalez, L. L., Garrie, K., & Turner, M. D. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.08.034 · Cited by 101
Brain Endothelial Hemostasis Regulation by Pericytes
Kim, J. A., Tran, N., Li, Z., Yang, F., Zhou, W., & Fisher, M. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600181 · Cited by 97
“Endothelial fibrinolysis is substantially influenced by the balance between tPA and PAI-1, and reduced fibrinolytic capacity predisposes to increased risk of thrombosis (Juhan-Vague et al, 2003).”
Background
What is the contribution of obesity to the metabolic syndrome?
Grundy, S. M. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.03.001 · Cited by 98
“Another factor, PAI-1, is released by adipose tissue in increased amounts with obesity [39]; this product should enhance the prothrombotic state.”
Background
Mixed Dyslipidemia, Metabolic Syndrome, Diabetes Mellitus, and Cardiovascular Disease: Clinical Implications
Cannon, C. P. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.067 · Cited by 99
Inflammatory Cytokines Interleukin-6 and Oncostatin M Induce Plasminogen Activator Inhibitor-1 in Human Adipose Tissue
Rega‐Kaun, G., Kaun, C., Weiss, T. W., Demyanets, S., Zorn, G., Kastl, S., Steiner, S., Seidinger, D., Kopp, C. W., Frey, M., et al. (2005) · Circulation · doi:10.1161/01.cir.0000161823.55935.be · Cited by 91
Resveratrol inhibits TNF-α-induced changes of adipokines in 3T3-L1 adipocytes
Ahn, J., Lee, H., Kim, S., & Ha, T. Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.10.109 · Cited by 89
Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis
Urano, T., Suzuki, Y., Iwaki, T., Sano, H., Honkura, N., & Castellino, F. (2019) · Current Drug Targets · doi:10.2174/1389450120666190715102510 · Cited by 89
Plasminogen Activator Inhibitor Type 1 Gene Polymorphism and Sepsis
Hermans, P. W. M., & Hazelzet, J. A. (2005) · Clinical Infectious Diseases · doi:10.1086/431996 · Cited by 87
Anti-inflammatory and antioxidant effects of polyphenols extracted from Antirhea borbonica medicinal plant on adipocytes exposed to Porphyromonas gingivalis and Escherichia coli lipopolysaccharides
Sage, F. L., Meilhac, O., & Gonthier, M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.020 · Cited by 94
Effects of Polyphenolic Compounds on Tumor Necrosis Factor-α (TNF-α)-Induced Changes of Adipokines and Oxidative Stress in 3T3-L1 Adipocytes
Yen, G., Chen, Y., Chang, W.-T., & Hsu, C. (2010) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf1036992 · Cited by 84
Epidemiology and Incidence: The Scope of the Problem and Risk Factors for Development of Venous Thromboembolism
Stein, P. D., & Matta, F. (2010) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2010.07.001 · Cited by 82
CCAAT/Enhancer Binding Proteinβin relation to ER Stress, Inflammation, and Metabolic Disturbances
van der Krieken, S. E., Popeijus, H. E., Mensink, R. P., & Plat, J. (2015) · BioMed Research International · doi:10.1155/2015/324815 · Cited by 81
Molecular mechanisms of tumor necrosis factor‐α‐mediated plasminogen activator inhibitor‐1 expression in adipocytes
Pandey, M., Loskutoff, D. J., & Samad, F. (2005) · The FASEB Journal · doi:10.1096/fj.04-3459fje · Cited by 84
“PAI-1 levels have consistently been shown to be dramatically upregulated in obese humans (4) and is thought to be the link between obesity, insulin-resistance, and increased risk for cardiovascular disease.”
Background
Obesity and pulmonary embolism: The mounting evidence of risk and the mortality paradox
Stein, P. D., Matta, F., & Goldman, J. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.10.019 · Cited by 81
“Increased plasminogen activator inhibitor-1 (PAI-1) has been reported in obese patients [21,22] and correlated with body mass index [23,24].”
Background
Hyperleptinemia without Obesity in Male Mice Lacking Androgen Receptor in Adipose Tissue
Yu, I.-C. I., Lin, H., Liu, N.-C., Wang, R.-S., Sparks, J. D., Yeh, S., & Chang, C. (2008) · Endocrinology · doi:10.1210/en.2007-0516 · Cited by 82
“• Androgen Receptor Roles in Adipocytokine Regulation Endocrinology, May 2008, 149(5):2361–2368 2363”
BackgroundInfluential
Endothelial Dysfunction, Inflammation and Diabetes
Dandona, P., Aljada, A., Chaudhuri, A., & Mohanty, P. (2004) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/b:remd.0000032407.88070.0a · Cited by 79
“The suppressive effect of TZDs and insulin is relevant since PAI1 concentration is elevated in pro-inflammatory states like the metabolic syndrome obesity and type 2 diabetes with an increase in the risk of atherosclerosis and its complications like acute myocardial infarction and stroke [64].”
Background
4G/5G polymorphism of PAI-1 gene is associated with multiple organ dysfunction and septic shock in pneumonia induced severe sepsis: prospective, observational, genetic study
Madách, K., Aladzsity, I., Szilágyi, Á., Füst, G., Gál, J., Pénzes, I., & Prohászka, Z. (2010) · Critical Care · doi:10.1186/cc8992 · Cited by 75
Hyperhomocysteinemia correlates with insulin resistance and low-grade systemic inflammation in obese prepubertal children
Martos, R., Valle, M., Morales, R. M., Cañete, R., Gavilan, M. I., & Sánchez‐Margalet, V. (2005) · Metabolism · doi:10.1016/j.metabol.2005.07.008 · Cited by 75
“At the same time, these proinflammatory cytokines, given off by adipose tissue, can lead to an increase in the secretion of PAI-1 [40].”
Background
Mediterranean diet and the metabolic syndrome
Esposito, K., Ciotola, M., & Giugliano, D. (2007) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200600297 · Cited by 77
Association of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer
Rajesh, Y., & Sarkar, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042163 · Cited by 75
“Its levels are high during obesity and IR [198,199].”
Background
Adipose tissue inflammation and liver pathology in human obesity
Tordjman, J., Guerre-Millo, M., & Clément, K. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)74601-9 · Cited by 71
Obesity is strongly and independently associated with a higher prevalence of pulmonary embolism
Movahed, M. R., Khoubyari, R., Hashemzadeh, M., & Hashemzadeh, M. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.01.003 · Cited by 70
Associations of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese
Qi, Q., Wang, J., Li, H., Yu, Z., Ye, X., Hu, F. B., Franco, O. H., Pan, A., Liu, Y., & Xu, L. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0427 · Cited by 68
Obesity and Thromboembolic Disease
Stein, P. D., & Goldman, J. (2009) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2009.05.006 · Cited by 67
Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery
Kröll, D., Stirnimann, G., Vogt, A. P., Lai, D. L. L., Borbély, Y., Altmeier, J., Schädelin, S., Candinas, D., Alberio, L., & Nett, P. C. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13243 · Cited by 67
Aucubin, a naturally occurring iridoid glycoside inhibits TNF-α-induced inflammatory responses through suppression of NF-κB activation in 3T3-L1 adipocytes
Park, K. S. (2013) · Cytokine · doi:10.1016/j.cyto.2013.04.005 · Cited by 64
Adipokines from white adipose tissue in regulation of whole body energy homeostasis
Sahu, B., & Bal, N. C. (2022) · Biochimie · doi:10.1016/j.biochi.2022.09.003 · Cited by 73
Increased levels of platelet activation markers are positively associated with carotid wall thickness and other atherosclerotic risk factors in obese patients
Nagy, B., Fülöp, T., Varga, Z., Karányi, Z., Magyar, M. T., Oláh, L., Papp, M., Facskó, A., Kappelmayer, J., Paragh, G., et al. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-01-0030 · Cited by 62
“Elevated PAI-1 antigen level was measured in patients with impaired glucose tolerance (46) and considered as a biochemical feature of insulin resistance syndrome (47).”
Background
Adipose Tissue and Atherothrombosis
Alessi, M., LIJNEN, H. R., Bastelica, D., & Juhan-Vague, I. (2003) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000083816 · Cited by 62
Self-citation
The ameliorating effect of carotenoid rich fraction extracted from Dunaliella salina microalga against inflammation- associated cardiac dysfunction in obese rats
El-Baz, F. K., Aly, H. F., & Abd-Alla, H. I. (2019) · Toxicology Reports · doi:10.1016/j.toxrep.2019.12.008 · Cited by 62
Adipose Tissue and Ceramide Biosynthesis in the Pathogenesis of Obesity
Samad, F., Badeanlou, L., Shah, C., & Yang, G. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0650-1_5 · Cited by 61
Cannabinoids in health and disease: pharmacological potential in metabolic syndrome and neuroinflammation
Mastinu, A., Premoli, M., Ferrari‐Toninelli, G., Tambaro, S., Maccarinelli, G., Memo, M., & Bonini, S. A. (2018) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2018-0013 · Cited by 62
Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity
Darmon, P., Dadoun, F., Boullu-Ciocca, S., Grino, M., Alessi, M.-C., & Dutour, A. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00654.2005 · Cited by 59
“Elevated plasma levels of PAI-1 have been found in patients with obesity, insulin resistance, and cardiovascular diseases (23, 48); moreover, PAI-1 excess has been shown to induce insulin resistance in adipocytes (27).”
BackgroundSelf-citation
Seabuckthorn Leaves Extract and Flavonoid Glycosides Extract from Seabuckthorn Leaves Ameliorates Adiposity, Hepatic Steatosis, Insulin Resistance, and Inflammation in Diet-Induced Obesity
Kwon, E., Lee, J., Kim, Y.-S., Do, A., Choi, J., Cho, S.-J., Jung, U. J., Lee, M., Park, Y., & Choi, M. (2017) · Nutrients · doi:10.3390/nu9060569 · Cited by 59
“In addition, IL-6 and PAI-1 are also pro-inflammatory cytokines synthesized by adipocyte, and its levels in plasma are increased in obesity and insulin resistance [42,43].”
Background
Early-Stage Alzheimer’s Disease Is Associated with Simultaneous Systemic and Central Nervous System Dysregulation of Insulin-Linked Metabolic Pathways
de la Monte, S. M., Tong, M., Daiello, L. A., & Ott, B. R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180906 · Cited by 63
Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone
Fanciulli, G., Delitala, A., & Delitala, G. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp005 · Cited by 56
Markers of Hemostasis and Systemic Inflammation in Heart Disease and Atherosclerosis in Smokers
MacCallum, P. K. (2005) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200406-036ms · Cited by 55
Metaflammatory responses during obesity: Pathomechanism and treatment
Debnath, M., Agrawal, S., Agrawal, A., & Dubey, G. P. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.10.012 · Cited by 58
“Increase in visceral fat mass results in eleation of circulating inflammatory mediators like -reactive protein, acute phase inflammatory proein and pro-inflammatory cytokines like adhesion nd remodelling molecule [94—96].”
Background
Adipokines and Cardiovascular Risk in Cushing’s Syndrome
Valassi, E., Biller, B. M. K., Klibanski, A., & Misra, M. (2011) · Neuroendocrinology · doi:10.1159/000330416 · Cited by 54
Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects
Al-Hamodi, Z. H., Ismail, I. S., Saif-Ali, R., Ahmed, K. A., & Muniandy, S. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-23 · Cited by 54
“The circulating PAI-1 levels are positively associated with obesity and insulin resistance [28-30].”
Background
Posterior Reversible Encephalopathy Syndrome After Transplantation: a Review
Chen, S., Hu, J., Xu, L., Brandon, D., Yu, J., & Zhang, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9560-0 · Cited by 52
“Previous research also reported that the inducers of PAI-1 involve the product of proinflammatory mediators, such as tumor necrosis factor-α and interleukin-1 [93, 94].”
Background
Obesity‐Associated Diseases Biomarkers Are Differently Modulated in Lean and Obese Individuals and Inversely Correlated to Plasma Polyphenolic Metabolites After 6 Weeks of Mango (Mangifera indica L.) Consumption
Fang, C., Kim, H., Barnes, R. C., Talcott, S. T., & Mertens‐Talcott, S. U. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201800129 · Cited by 53
Metabolic Syndrome: The Constellation of Co-morbidities, A Global Threat
Madan, K., Paliwal, S., Sharma, S. K., Kesar, S., Chauhan, N., & Madan, M. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530323666230309144825 · Cited by 55
Association of serum uric acid levels to inflammation biomarkers and endothelial dysfunction in obese prepubertal children
Valle, M., Martos, R., Cañete, M. D., Valle, R., van Donkelaar, E. L., Bermudo, F., & Cañete, R. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12199 · Cited by 49
The Ternary Complex Factor Net Regulates Cell Migration through Inhibition of PAI-1 Expression
Buchwalter, G., Gross, C., & Wasylyk, B. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.10853-10862.2005 · Cited by 48
Plasminogen activator inhibitor 1 (PAI‐1): in vitro activities and clinical relevance
Horrevoets, A. J. G. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04844.x · Cited by 48
Plasminogen Activator Inhibitor-1 in Obstructive Sleep Apnea Patients with and without Hypertension
Zamarrón, C., Ricoy, J., Riveiro, A., & Gudé, F. (2008) · Lung · doi:10.1007/s00408-008-9076-8 · Cited by 45
“Increased fibrinogen blood levels and decreased fibrinolytic activity associated with elevated concentrations of PAI-1 increase the risk of thrombosis and atherosclerosis in these patients [34].”
Background

Authors: Juhan-Vague, I., Alessi, M.-C., Mavri, A., & Morange, P. E.
Affiliations: Inserm (FR)
Corresponding author: Juhan-Vague, I.
ORCID: Alessi, M-C.
Mavri, A.
Morange, P.E.
Venue: Journal of Thrombosis and Haemostasis
Publisher: Elsevier BV
Published: 2003-07
Volume: 1
Issue: 7
Pages: 1575-1579
ISSN: 1538-7836 (ISSN-L)
DOI: 10.1046/j.1538-7836.2003.00279.x
OpenAlex: W2042742088
Cited by: 371
References: 95
Citations by year: 2026: 9 · 2025: 13 · 2024: 13 · 2023: 8 · 2022: 14 · 2021: 6 · 2020: 11 · 2019: 14 · 2018: 10 · 2017: 17 · 2016: 9 · 2015: 19 · 2014: 14 · 2013: 11 · 2012: 13
FWCI: 4.40
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 7104 d)
Locations: Journal of Thrombosis and Haemostasis (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Keywords: plasminogen activator inhibitor-1, metabolic syndrome, inflammation, obesity, adipose tissue, inflammatory cytokines, impaired fibrinolysis, atherothrombosis, vascular risk, PAI-1 inhibitors, atherosclerosis
MeSH terms: Animals, Heart Diseases, Humans, Insulin Resistance, Obesity, Risk, Plasminogen Activator Inhibitor 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks